Log In Get Started
Insider Trading April 17, 2026 08:03 PM

IBEX Director Disposes $162,809 in Shares Amid Active Buybacks and Strong Quarterly Results

Daniella Ballou-Aares reduced her stake in multiple trades; company posted better-than-expected Q2 FY2026 results and continues repurchasing stock

By Nina Shah IBEX
IBEX Director Disposes $162,809 in Shares Amid Active Buybacks and Strong Quarterly Results
IBEX

Daniella Ballou-Aares, a director at IBEX Ltd (NASDAQ: IBEX), sold $162,809 worth of common shares across transactions in March and December 2025. The director now holds 10,643 shares. The stock trades at $29.72, down roughly 18% over six months, while InvestingPro flags a P/E of 9.8 and notes management share repurchases. IBEX reported stronger-than-expected Q2 FY2026 results, with revenue of $164.2 million and adjusted EPS of $0.87.

Key Points

  • Director Daniella Ballou-Aares sold $162,809 in IBEX common stock across transactions in March and December 2025; she now directly owns 10,643 shares.
  • IBEX shares are trading at $29.72, down roughly 18% over the last six months, while InvestingPro identifies a P/E of 9.8 and notes active management share repurchases.
  • IBEX reported strong Q2 FY2026 results: revenue of $164.2 million (up 16.7% year over year) and adjusted EPS of $0.87 (up 46%), beating analyst expectations.

Daniella Ballou-Aares, a member of IBEX Ltd's board, executed a series of common-stock sales totaling $162,809, according to a Form 4 filing with the Securities and Exchange Commission.

The filing details two transactions on March 13, 2025, when Ballou-Aares sold 5,843 shares at $24.2175 per share and 157 shares at $24.2114 per share. Later in the year, on December 2, 2025, she sold an additional 500 shares at $35.01 per share. Across these trades, the prices ranged from $24.2114 to $35.01 per share.

After completing the sales noted in the filing, Ballou-Aares directly owns 10,643 shares of IBEX Ltd.

Market context provided in the filing and subsequent market data show IBEX shares trading at $29.72, representing a decline of roughly 18% over the past six months. Independent analysis from InvestingPro, referenced in public materials about the company, characterizes the stock as appearing undervalued at current levels, citing a price-to-earnings ratio of 9.8. The same analysis highlights that management has been actively repurchasing shares - one of the 11+ InvestingPro Tips available for deeper review - and notes that a Pro Research Report covering IBEX is available alongside reports on more than 1,400 other U.S. equities.

Separately, IBEX disclosed strong financial performance in its second quarter of fiscal year 2026. The company reported revenue of $164.2 million, a 16.7% increase from the comparable period a year earlier. Adjusted earnings per share for the period were $0.87, a rise of 46% year over year. Those results exceeded analyst expectations, and the company’s shares rose during aftermarket trading following the release. Analysts continue to monitor IBEX's progress in light of these results.

The Form 4 filing documents precise transaction details and current holdings but does not provide the director's intentions behind the sales. The combination of insider selling, management repurchases, a recent pullback in the share price, and stronger-than-expected quarterly results presents a mixed data set for investors weighing IBEX's outlook.

Readers seeking deeper coverage of the stock and underlying metrics can consult the InvestingPro resources mentioned above, which include valuation metrics and additional tips for further analysis.

Risks

  • Insider selling may be perceived negatively by investors and could contribute to short-term share-price pressure - impacts equity markets and investor sentiment.
  • The stock has fallen roughly 18% over the past six months, indicating price volatility that could affect market participants and portfolio positioning.
  • Although recent quarterly results exceeded expectations, analysts will continue to monitor the company's performance, introducing uncertainty about future earnings trajectory and market reaction.

More from Insider Trading

OrbiMed Expands Stake in Traws Pharma via Strategic Private Placement Apr 28, 2026 Rexford Industrial Realty General Counsel Completes $1.18 Million Stock Sale Apr 28, 2026 Bicara Therapeutics CMO Executes Rule 10b5-1 Trading Plan Involving Share Sales and Option Exercises Apr 28, 2026 Abbott Laboratories Director Daniel Starks Executes Substantial Open Market Share Purchase Apr 28, 2026 BlackRock President Robert Kapito Executes $9.2 Million Share Sale Apr 28, 2026